Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | WDR44 | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
mRNA | ING1 | CTRPv2 | pan-cancer | AAC | 0.13 | 3e-05 |
mRNA | RP4-533D7.6 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | RP11-214K3.25 | CTRPv2 | pan-cancer | AAC | 0.14 | 3e-05 |
mRNA | TBC1D24 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | SGMS1 | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | GPHN | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | GTSE1 | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
mRNA | CTC-326K19.6 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |
mRNA | SPNS3 | CTRPv2 | pan-cancer | AAC | 0.14 | 4e-05 |